drugset / Trial / NCT03458117

T-VEC in Non-melanoma Skin Cancer

NCT03458117

Phase 1 Completed 26 enrolled University of Zurich
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.

Timeline

Start
2018-04-19
Primary completion
2022-02-04
Completion
2022-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 4 ml Other